NorthLinks Bio
News & Updates
Latest News
Press Release | June 23, 2026
NorthLinks Bio Launches with $34 Million Financing to Advance Broad-Spectrum Respiratory Antiviral Platform
READ MOREPublications
Springer Nature | July 2025
A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge.
READ MOREScienceDirect | August 2024
HEX17(Neumifil): An intranasal respiratory biotherapeutic with broad-acting antiviral activity.
READ MORE PNAS | April 2014
Prevention of influenza by targeting host receptors using engineered proteins.
READ MORE Connect with the NorthLinks Bio team.
Get in Touch
